Bruker (NASDAQ:BRKR) Releases Earnings Results, Beats Expectations By $0.08 EPS

Bruker (NASDAQ:BRKR) released its quarterly earnings results on Wednesday. The medical research company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08, FiscalAI reports. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The firm had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. During the same quarter in the prior year, the firm earned $0.47 EPS. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker’s conference call:

• Q1 results beat expectations with reported revenue of $823.4M (+2.7% reported, organic -4.4%) and non‑GAAP EPS of $0.31, and management reconfirmed full‑year guidance of $3.57B–$3.60B revenue and $2.10–$2.15 non‑GAAP EPS.
• Order momentum strengthened—BSI organic bookings grew in the high single digits and book‑to‑bill stayed >1 for the third consecutive quarter—management expects a return to organic revenue growth in Q2 (low‑ to mid‑single digits).
• Several idiosyncratic, AI‑driven growth engines are accelerating performance, including semi‑metrology (now >$300M annual), SciY lab‑digitization/software (~$50M), security detection (~$70M), and large multi‑year BEST superconductor orders, which management says provide durable secular tailwinds.
• Margins were pressured in Q1 (non‑GAAP gross margin 50%, operating margin 10.2%) by FX, tariffs and mix, but management expects a 250–300 bp non‑GAAP operating margin expansion in 2026 driven by cost‑savings (now tracking ~$140M annualized), though execution and macro risks remain.

Bruker Stock Down 0.5%

Shares of BRKR traded down $0.21 during midday trading on Friday, hitting $43.52. The company had a trading volume of 713,301 shares, compared to its average volume of 2,284,377. The company’s 50-day simple moving average is $37.26 and its 200-day simple moving average is $42.06. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.87 and a current ratio of 1.55. Bruker has a 1 year low of $28.53 and a 1 year high of $56.22. The firm has a market capitalization of $6.62 billion, a P/E ratio of -181.32, a P/E/G ratio of 2.53 and a beta of 1.12.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on BRKR shares. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, April 24th. The Goldman Sachs Group cut their price objective on shares of Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a research report on Friday, February 13th. TD Cowen boosted their target price on shares of Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a report on Thursday. Stifel Nicolaus set a $45.00 price target on shares of Bruker in a research note on Friday. Finally, Citigroup upped their target price on shares of Bruker from $40.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $50.54.

Insider Buying and Selling

In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the sale, the vice president directly owned 128,443 shares in the company, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 27.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Allworth Financial LP boosted its holdings in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares in the last quarter. Federated Hermes Inc. increased its position in Bruker by 6.7% during the fourth quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock worth $284,000 after buying an additional 380 shares during the period. Parallel Advisors LLC lifted its stake in Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Bruker during the fourth quarter worth approximately $26,000. Finally, UMB Bank n.a. increased its holdings in shares of Bruker by 57.9% in the 4th quarter. UMB Bank n.a. now owns 1,571 shares of the medical research company’s stock valued at $74,000 after acquiring an additional 576 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.